Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Immuneering Corporation
Market Cap
$144.48M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$144.00M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
-394.61%
5Y Avg
-639.25%
Market Cap
$150.23M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-76.15%
Market Cap
$147.13M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$142.15M
Gross Margin
57.63%
TTM Avg
59.89%
3Y Avg
61.87%
5Y Avg
62.78%
Market Cap
$139.73M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
Market Cap
$139.63M
Gross Margin
81.26%
TTM Avg
40.63%
3Y Avg
20.32%
5Y Avg
13.54%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $144.48M | 0.00% | 0.00% | 0.00% | 0.00% |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.00M | 100.00% | 100.00% | -394.61% | -639.25% |
| Nyxoah S.A. (NYXH)vs › | $142.60M | 63.13% | 64.40% | 63.36% | 62.40% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $150.23M | 0.00% | 0.00% | 0.00% | -76.15% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.13M | 0.00% | 0.00% | 0.00% | 0.00% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | 85.91% | 84.21% | 85.09% | 82.87% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | 57.63% | 59.89% | 61.87% | 62.78% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 62.53% | 65.36% | 65.75% | 64.06% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | 81.26% | 40.63% | 20.32% | 13.54% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | 0.00% | 0.00% | 0.00% | -29.98% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 100.00% |
| 2022-09-30 | 49.60% |
| 2022-06-30 | -165.09% |
| 2022-03-31 | 50.55% |
| 2021-12-31 | -8.77% |
| 2021-09-30 | 54.56% |
| 2021-06-30 | 51.73% |
| 2021-03-31 | 45.31% |
| 2020-12-31 | 28.85% |
| 2020-09-30 | 53.85% |
| 2020-06-30 | 50.70% |
| 2020-03-31 | 47.21% |
